Wistar study proposes hypothesis of how Epstein-Barr virus infects host

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

A novel treatment approach that combines a targeted therapy drug with hormone therapy significantly increased the amount of time a person with stage 2 or 3 HR-positive, HER2-negative early breast cancer lives without the cancer returning, according to a phase III trial co-led by UCLA Health Jonsson Comprehensive Cancer Center investigators.

March 29, 2024

Vol.50 No.13

Clinical Roundup

Wistar scientists discover link between leaky gut and accelerated biological aging

The Wistar Institute’s associate professor Mohamed Abdel-Mohsen demonstrated, with his lab and collaborators, a connection between viral damage to the gut and premature biological aging.

February 23, 2024

Vol.50 No.08

Drugs & Targets

FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors

FDA has accepted the supplemental New Drug Application for Augtyro (repotrectinib) for the treatment of adult and pediatric patients 12 years of age and older with solid tumors that have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion, and are locally advanced or metastatic or where surgical resection is likely to result in severe morbidity.

February 16, 2024

Vol.50 No.07

Funding Opportunities

Helen F. Graham Cancer Center, Wistar establish Caspar Wistar Bacchieri Disparities Fellowship

The Helen F. Graham Cancer Center & Research Institute at ChristianaCare, in partnership with the Wistar Cancer Institute, established a Caspar Wistar Bacchieri Disparities Fellowship in Cancer Population Health Science.

January 12, 2024

Vol.50 No.02

Clinical Roundup

Wistar study finds that common cholesterol drug enhances cell-based therapy

A team of Wistar researchers led by Hildegund C.J. Ertl—a professor in The Wistar Institute’s Vaccine & Immunotherapy Center—has demonstrated that the common cholesterol drug fenofibrate can boost T cells’ ability to destroy human tumors. The study was published in Molecular Therapy Oncolytics.

December 15, 2023

Vol.49 No.46

In Brief

The Max Foundation provides targeted treatment for advanced breast cancer patients in Mozambique at no cost

Three patients in Mozambique have started treatment for HER2- HR+ advanced breast cancer, including CDK4/6 inhibitor therapy through The Max Foundation’s Max Access Solutions program.

November 10, 2023

Vol.49 No.42

Wistar study proposes hypothesis of how Epstein-Barr virus infects host

YOU MAY BE INTERESTED IN

UCLA: Adding ribociclib to hormone therapy reduces the risk of breast cancer recurrence

Wistar scientists discover link between leaky gut and accelerated biological aging

FDA grants Augtyro priority review for NTRK-positive locally advanced or metastatic solid tumors

Helen F. Graham Cancer Center, Wistar establish Caspar Wistar Bacchieri Disparities Fellowship

Wistar study finds that common cholesterol drug enhances cell-based therapy

The Max Foundation provides targeted treatment for advanced breast cancer patients in Mozambique at no cost

Renew today!

Subscriber content

Login